Back to results
US 12,760,373 B2Granted
Biomarkers for predicting the response to checkpoint inhibitors
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsToshiki Iwai, Masamichi Sugimoto
Life of this patent
Estimating the term…
Abstract
The invention provides biomarkers for predicting the response to checkpoint inhibitors. The inventors demonstrate that a PD-1/PD-L1 inhibitor exerts antitumor activity against tumor with low PD-L1 expression and immune-desert phenotype through blocking PD-L1 in the lymph nodes. The invention provides novel combinations of intratumoral markers for antigen cross-presenting cells and T cell chemokines which are expected to be superior efficacy-predicting biomarkers compared to existing methods.
Claims8
A method of treating a patient who has a cancer, the method comprising:
- (i) assaying, or having assayed, an mRNA expression level of XCRI in a sample from the patient comprising tumor cells or cells of a tumor-draining lymph node;
- (ii) assaying, or having assayed, an mRNA expression level of each of CXCL9, CXCL10, and CXCL11 in a sample from the patient comprising tumor cells;
- (iii) based on an average of the mRNA expression levels of XCR1, CXCL9, CXCL10, and CXCL11 as assayed in (i) and (ii), determining that the patient's cancer is likely responsive to treatment with a PD-1/PD-L1 inhibitor;
- and
- (iv) treating the patient with the PD-1/PD-L1 inhibitor.
2 more elements
Dependencies are inferred from the claim text.